Perspectives and advancements in the design of nanomaterials for targeted cancer theranostics.

Tan, YY; Yap, PK; Xin Lim, GL; Mehta, M; Chan, Y; Ng, SW; Kapoor, DN; Negi, P; Anand, K; Singh, SK; Jha, NK; Lim, LC; Madheswaran, T; Satija, S; Gupta, G; Dua, K; Chellappan, DK

Perspectives and advancements in the design of nanomaterials for targeted cancer theranostics.

Tan, YY Yap, PK Xin Lim, GL Mehta, M Chan, Y Ng, SW Kapoor, DN Negi, P Anand, K Singh, SK Jha, NK Lim, LC Madheswaran, T Satija, S

Gupta, G Dua, K

Chellappan, DK

Permalink

Publisher:: Elsevier BV
Publication Type:: Journal Article
Citation:: Chemico-biological interactions, 2020, 329
Issue Date:: 2020-08-06

Closed Access

	Filename	Description	Size
	1-s2.0-S0009279720310231-main.pdf	Published version	6.29 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Tan, YY
dc.contributor.author	Yap, PK
dc.contributor.author	Xin Lim, GL
dc.contributor.author	Mehta, M
dc.contributor.author	Chan, Y
dc.contributor.author	Ng, SW
dc.contributor.author	Kapoor, DN
dc.contributor.author	Negi, P
dc.contributor.author	Anand, K
dc.contributor.author	Singh, SK
dc.contributor.author	Jha, NK
dc.contributor.author	Lim, LC
dc.contributor.author	Madheswaran, T
dc.contributor.author	Satija, S https://orcid.org/0000-0003-4702-6534
dc.contributor.author	Gupta, G
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.contributor.author	Chellappan, DK
dc.date.accessioned	2020-09-01T05:49:59Z
dc.date.available	2020-08-03
dc.date.available	2020-09-01T05:49:59Z
dc.date.issued	2020-08-06
dc.identifier.citation	Chemico-biological interactions, 2020, 329
dc.identifier.issn	0009-2797
dc.identifier.issn	1872-7786
dc.identifier.uri	http://hdl.handle.net/10453/142469
dc.description.abstract	Cancer continues to be one of the most challenging diseases to be treated and is one of the leading causes of deaths around the globe. Cancers account for 13% of all deaths each year, with cancer-related mortality expected to rise to 13.1 million by the year 2030. Although, we now have a large library of chemotherapeutic agents, the problem of non-selectivity remains the biggest drawback, as these substances are toxic not only to cancerous cells, but also to other healthy cells in the body. The limitations with chemotherapy and radiation have led to the discovery and development of novel strategies for safe and effective treatment strategies to manage the menace of cancer. Researchers have long justified and have shed light on the emergence of nanotechnology as a potential area for cancer therapy and diagnostics, whereby, nanomaterials are used primarily as nanocarriers or as delivery agents for anticancer drugs due to their tumor targeting properties. Furthermore, nanocarriers loaded with chemotherapeutic agents also overcome biological barriers such as renal and hepatic clearances, thus improving therapeutic efficacy with lowered morbidity. Theranostics, which is the combination of rationally designed nanomaterials with cancer-targeting moieties, along with protective polymers and imaging agents has become one of the core keywords in cancer research. In this review, we have highlighted the potential of various nanomaterials for their application in cancer therapy and imaging, including their current state and clinical prospects. Theranostics has successfully paved a path to a new era of drug design and development, in which nanomaterials and imaging contribute to a large variety of cancer therapies and provide a promising future in the effective management of various cancers. However, in order to meet the therapeutic needs, theranostic nanomaterials must be designed in such a way, that take into account the pharmacokinetic and pharmacodynamics properties of the drug for the development of effective carcinogenic therapy.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Elsevier BV
dc.relation.ispartof	Chemico-biological interactions
dc.relation.isbasedon	10.1016/j.cbi.2020.109221
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	0601 Biochemistry and Cell Biology
dc.subject.classification	Toxicology
dc.title	Perspectives and advancements in the design of nanomaterials for targeted cancer theranostics.
dc.type	Journal Article
utslib.citation.volume	329
utslib.location.activity	Ireland
utslib.for	0601 Biochemistry and Cell Biology
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Pharmacy
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health
utslib.copyright.status	closed_access	*
pubs.consider-herdc	false
dc.date.updated	2020-09-01T05:49:53Z
pubs.publication-status	Published
pubs.volume	329

Abstract:

Cancer continues to be one of the most challenging diseases to be treated and is one of the leading causes of deaths around the globe. Cancers account for 13% of all deaths each year, with cancer-related mortality expected to rise to 13.1 million by the year 2030. Although, we now have a large library of chemotherapeutic agents, the problem of non-selectivity remains the biggest drawback, as these substances are toxic not only to cancerous cells, but also to other healthy cells in the body. The limitations with chemotherapy and radiation have led to the discovery and development of novel strategies for safe and effective treatment strategies to manage the menace of cancer. Researchers have long justified and have shed light on the emergence of nanotechnology as a potential area for cancer therapy and diagnostics, whereby, nanomaterials are used primarily as nanocarriers or as delivery agents for anticancer drugs due to their tumor targeting properties. Furthermore, nanocarriers loaded with chemotherapeutic agents also overcome biological barriers such as renal and hepatic clearances, thus improving therapeutic efficacy with lowered morbidity. Theranostics, which is the combination of rationally designed nanomaterials with cancer-targeting moieties, along with protective polymers and imaging agents has become one of the core keywords in cancer research. In this review, we have highlighted the potential of various nanomaterials for their application in cancer therapy and imaging, including their current state and clinical prospects. Theranostics has successfully paved a path to a new era of drug design and development, in which nanomaterials and imaging contribute to a large variety of cancer therapies and provide a promising future in the effective management of various cancers. However, in order to meet the therapeutic needs, theranostic nanomaterials must be designed in such a way, that take into account the pharmacokinetic and pharmacodynamics properties of the drug for the development of effective carcinogenic therapy.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/142469